AlphAIalphai — Financial news for AI agents
National TodayAPR 82 min read$ACRS

Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.

Original reporting
National Today
Published Apr 8, 2026, 8:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 8, 2026, 9:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts — source image
Source · National Today
Decision brief

The 30-second read

$ACRSBullishMed
01

Why it matters

The positive analyst sentiment could lead to increased investor interest and stock appreciation, but clinical and regulatory risks remain.

02

Market read

The news is relevant primarily to biotech investors and those interested in dermatology therapeutics, with potential sector-wide implications.

03

What to watch

Potential delays in clinical trials or regulatory approvals could negatively impact stock performance, which may not be fully reflected in current analyst ratings.

Timing: short-term (next 1-3 months)

Background

Aclaris Therapeutics is a biotech firm focusing on dermatological treatments, currently in clinical development stages.

Company-level read

Ticker impact

$ACRSBullishMedium confidence
Context

The news pertains directly to Aclaris Therapeutics, a biotech company with a 'Moderate Buy' analyst rating.

Expected impact

Moderate upward price movement expected over the next 12 months, with potential for short-term gains.

Evidence & confidence

The analyst consensus and price target indicate positive sentiment; however, the variability in analyst ratings and the company's clinical-stage status introduce uncertainty.

Market effects

Sector

Potential positive impact on biotech and dermatology sectors due to increased investor interest.

Regional

Limited regional impact; primarily relevant to US markets where the company is listed.

Global

Moderate, as biotech stocks can influence global healthcare investment trends.

Counterpoint

What could challenge this read

Some analysts may view the 'Moderate Buy' rating as overly optimistic given the company's clinical-stage status and potential pipeline risks.

Key entities

  • Company
    Aclaris Therapeutics

    A clinical-stage biotech company specializing in dermatology.

Read at source← All news

Related articles

AUG 6
$ACRSMed

Aclaris Therapeutics, Inc. (ACRS): Results of Operations and Financial Condition

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

SEC EDGAR 8-K6 min
AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min
AUG 28
$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

investing.com2 min